Bernardo Wealth Planning LLC Sells 376 Shares of Johnson & Johnson (NYSE:JNJ)

Bernardo Wealth Planning LLC trimmed its stake in Johnson & Johnson (NYSE:JNJ) by 5.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,338 shares of the company’s stock after selling 376 shares during the period. Bernardo Wealth Planning LLC’s holdings in Johnson & Johnson were worth $900,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. IFS Advisors LLC raised its holdings in shares of Johnson & Johnson by 138.9% in the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after buying an additional 100 shares during the period. Highline Wealth Partners LLC purchased a new position in Johnson & Johnson during the 3rd quarter worth $31,000. RPg Family Wealth Advisory LLC purchased a new position in Johnson & Johnson during the 3rd quarter worth $35,000. Mowery & Schoenfeld Wealth Management LLC increased its holdings in Johnson & Johnson by 58.7% during the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock worth $40,000 after purchasing an additional 91 shares during the period. Finally, Activest Wealth Management purchased a new position in Johnson & Johnson during the 3rd quarter worth $40,000. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $147.03 on Tuesday. The stock has a 50-day moving average of $148.51 and a two-hundred day moving average of $156.10. Johnson & Johnson has a one year low of $140.68 and a one year high of $168.85. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. The stock has a market cap of $353.99 billion, a P/E ratio of 21.28, a P/E/G ratio of 2.30 and a beta of 0.51.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be issued a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.37%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 71.78%.

Insider Activity

In related news, Director Mark A. Weinberger acquired 1,000 shares of the firm’s stock in a transaction dated Thursday, December 12th. The stock was acquired at an average price of $147.22 per share, with a total value of $147,220.00. Following the acquisition, the director now directly owns 1,000 shares in the company, valued at $147,220. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

JNJ has been the topic of a number of analyst reports. Citigroup cut their price target on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. Royal Bank of Canada lifted their price target on Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a report on Wednesday, October 16th. Guggenheim lifted their price target on Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a report on Wednesday, November 6th. Morgan Stanley lifted their price target on Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a report on Wednesday, October 16th. Finally, Bank of America cut their price target on Johnson & Johnson from $166.00 to $160.00 and set a “neutral” rating on the stock in a report on Friday. Seven analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $174.29.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.